Tvardi Therapeutics (NASDAQ:TVRD) Stock Gets Downgrade from Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Monday, Wall Street Zen reports.

Other equities analysts also recently issued research reports about the stock. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, October 2nd. Lucid Cap Mkts raised shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. BTIG Research decreased their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Finally, Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $1.04 on Monday. Tvardi Therapeutics has a 52-week low of $0.93 and a 52-week high of $7.23. The firm has a 50 day moving average price of $1.62 and a two-hundred day moving average price of $2.52.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Equities analysts expect that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $181,000. Susquehanna International Group LLP acquired a new position in shares of Tvardi Therapeutics during the second quarter worth approximately $63,000. Finally, GSA Capital Partners LLP bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth $34,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.